A Phase 1/2 interventional study of Ubamatamab and Cemiplimab in Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer and Recurrent Primary Peritoneal Cancer, sponsored by Regeneron Pharmaceuticals. Recruiting at 54 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 48th largest by planned enrollment of the 1,498 interventional ones that give a count, is one of 76 that started in 2018, is one of 222 in phase 1/2, reaches primary completion later than 192 of the 452 other live ones, and was the 1,120th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Michael J. Goodheart · Sites in United States
Ages 18–99 · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Israel, Taiwan
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+
GE Healthcare · Sites in United States, Sweden
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,779 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 769 · Phase 2 718 · Phase 3 114 · Phase 4 8
First in 1980; this study’s year is marked. 76 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 890 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 47 across the 1,498 interventional studies, 176 across the 195 observational. Of the 1,209 that completed or were terminated, 445 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
713 of 1,779 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 4 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
162 of the studies in Ovarian Neoplasms with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05281471Phase 3Genelux CorporationEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | 2026-12 |
| NCT04498117Phase 3CanariaBio Inc.Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | 2026-12-26 |
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04095364Phase 3NRG OncologyLetrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | 2027-02-01 |
Add all 162 to your calendar (.ics) → With an account.
Among the 1,779 studies in Ovarian Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to:
Key Inclusion Criteria:
Ovarian Cancer Cohorts Only: Patients with or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following:
Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-Programmed Cell Death Ligand 1 () therapy and platinum-based chemotherapy:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
REGN4018 administration
Drug: Ubamatamab · Drug: Sarilumab · Drug: Tocilizumab
REGN4018 and cemiplimab administration
Drug: Ubamatamab · Drug: Cemiplimab
Administered per the protocol
Also known as: REGN4018
Administered per the protocol
Also known as: REGN2810, Libtayo®
Administered per the protocol
Also known as: Kevzara®, REGN88, SAR153191
Administered per the protocol
Also known as: ACTEMRA®, Biosimilar
Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy
Dose Escalation Phase
Time frame: From Cycle 1, Day 1 up to 35 days
Number of participants with DLTs for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: From Cycle 2, Day 1 up to 21 days
Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (imAEs)) for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with serious adverse events (SAEs) for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with SAEs for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Number of deaths for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
Number of deaths for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Concentration of ubamatamab in serum over time for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
Concentration of ubamatamab in serum over time for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
ORR defined by RECIST 1.1 for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
ORR based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation Phase
Time frame: Up to 2 years
ORR based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation Phase
Time frame: Up to 2 years
Number of participants with TEAEs (including imAEs) for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Number of participants with TEAEs (including imAEs) for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Number of participants with SAEs for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Number of participants with SAEs for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Number of deaths for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Number of deaths for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Concentration of ubamatamab in serum over time for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Concentration of ubamatamab in serum over time for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for ubamatamab monotherapy
Dose Expansion Phase The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: Baseline up to 2 years
Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Baseline up to 2 years
Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Baseline up to 2 years
Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Baseline up to 2 years
Change from baseline in abdominal symptoms as measured by the Measure of Ovarian Symptoms and Treatment (MOST)-Abdominal index score for ubamatamab monotherapy
Dose Expansion Phase excluding the Endometrial Cancer Cohort The MOST-24 is a 24-item questionnaire used to measure the impact of chemotherapy on symptoms (21 items) and well-being (3 items). The expected questionnaire completion time is less than 5 minutes. The prevalence of each MOST item at assessment time points can be summarized by providing the mean, standard deviation and proportions based on the MOST response format, a numeric rating scale with integers from zero to 10, with five verbal anchors: 'No trouble at all' (0), 'Mild' (1-3), 'Moderate' (4-6), 'Severe' (7-10), and 'Worst I can imagine' (10).
Time frame: Baseline up to 2 years
Change from baseline in abdominal symptoms as measured by the MOST-Abdominal index score for ubamatamab with cemiplimab
Dose Expansion Phase Not applicable to Endometrial Cancer Cohort
Time frame: Baseline up to 2 years
Time to deterioration in GHS/QoL for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Time to deterioration in GHS/QoL for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Time to deterioration in physical functioning for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Time to deterioration in physical functioning for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Time to deterioration in abdominal symptoms for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Up to 2 years
Time to deterioration in abdominal symptoms for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Up to 2 years
Change from baseline in QoL as measured by EQ-5D for ubamatamab monotherapy
Dose Expansion Phase
Time frame: Baseline up to 2 years
Change from baseline in QoL as measured by EQ-5D for ubamatamab with cemiplimab
Dose Expansion Phase
Time frame: Baseline up to 2 years
ORR based on iRECIST for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
ORR based on iRECIST for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Best overall response (BOR) based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
BOR based on iRECIST for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
BOR based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
BOR based on iRECIST for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Duration of response (DOR) based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
DOR based on iRECIST for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
DOR based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
DOR based on iRECIST for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Disease control rate based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Disease control rate based on iRECIST for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Disease control rate based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Disease control rate based on iRECIST for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Complete response (CR) rate based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
CR rate based on iRECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
CR rate based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
CR rate based on iRECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Progression-free survival (PFS) based on RECIST 1.1 for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
PFS based on iRECIST for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
PFS based on RECIST 1.1 for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
PFS based on iRECIST for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Cancer antigen-125 (CA-125) response for ubamatamab monotherapy
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
CA-125 response for ubamatamab with cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Presence or absence of anti-drug antibodies against ubamatamab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Presence or absence of anti-drug antibodies against cemiplimab
Dose Escalation and Dose Expansion Phases
Time frame: Up to 2 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Started May 2018 (actual). Primary completion is estimated for May 2027, 107 months after the start.
Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's planned 107 months is above that.
Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab